🗣:🇺🇸/👥️:👨‍⚕️🦀🩸 Pregnancy and CMPNs youtu.be/4-JxhxYxnKQ?si…

🗣:🇺🇸/👥️:👨‍⚕️🦀🩸 Has cost-effectiveness of TKI cessation changed over time? Before the introduction of generic TKIs, cessation was considered cost-effective. However, w/ the advent of generic TKIs it is not! Presented by Elias Jabbour, MD at #Soho2024 Data: Hagop Kantarjian,MD

University Health Network American Philatelic Society Answer: It's a little hard to see, but type O blood does not cause agglutination with one anti-serum but not with the other. I suspect labels for O and B were switched - though could also be a 3 way switch between O/A/B, since we're not told if top panels are anti-A or anti-B.

👌Heritable BP Syndromes renalfellow.org/2018/11/19/raa… Renal Fellow Network

Bispecific antibodies in the treatment of multiple myeloma nature.com/articles/s4140… #mmsm

An intense debate on choice of induction therapy for older adult AML (60+ age) at #iWAL204 Drs. Tapan Kadia and Wang believe it’s time for 7+3 to retire with dignity… and let the next generation of LI therapies lead They make a pretty convincing argument! 🗳️ ✅

The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas ow.ly/CXRr50TkrZB #drugadvances #clinicaltrialsandobservations #immunobiologyandimmunotherapy #lymphoidneoplasia

Harrison is one of the most amazing teaching books ever produced A short thread on brilliant educational algorithms in internal medicine

Menin inhibitors are the most exciting class of drugs in development for AML. a very nice summary of menin-i development timeline & outcome data w/ menin-i combination therapies by Ghayas Issa Joshua Zeidner MD Eunic Wang Chaired by Naval Daver, M.D. at #iWAL24 #menin #leusm

👉Polycythemia vera: past, present and future: Leukemia & Lymphoma | Dr ⁦⁦Ami Patel, MD⁩ Dr ⁦Lucia Masarova, MD⁩ Dr ⁦Ruben A. Mesa, MD⁩ Dr ⁦Gaby Hobbs⁩ ⁦Naveen Pemmaraju, MD⁩ | #MPNSM tandfonline.com/doi/full/10.10…

🗣:🇺🇸/👥️:👨‍⚕️🦀🩸 Look! What I have learned from MD Anderson (Naveen Pemmaraju, MD) today: Blastic plasmocytoid dendritic cell Neoplasms present with CD123456 💡 positivity: CD123, CD4, CD56 positive.

👉👉👉Thank you 🙏 G Garcia-Manero Tapan Kadia Dr Julie Braish & Mrs Crystal Mullen for the invitation to speak to our brilliant MD Anderson Cancer Center #LeukemiaFellows this evening about #BPDCN during the well-attended Leukemia Fellow Lecture Series! 👏 #meded #leusm #endcancer Mehmet Sevki Uyanik, MD

Our group Mayo Clinic validated Next Gen flow (NGF) for MRD assessment in myeloma and secured FDA IDE for use in a clinical trial as an integral biomarker. Congrats Dragan Jevremovic Horatiu Olteanu and Shaji Kumar for your leadership. Mayo Myeloma onlinelibrary.wiley.com/doi/10.1002/aj…

Happy to see our trial of DAC, venetoclax and ponatinib for advanced phase CML published in The Lancet Haematology. Response rate was 80%, allowing for bridge to alloSCT. Still a lot more work to be done in this rare disease. We have new TKI combo studies now open and enrolling.

🗣:🇺🇸/👥️:👨‍⚕️🦀🩸 Intriguing data regarding the usage of CD-19 positive CAR-T cells in the treatment of aberrant CD19 positive AML. As it is well known that t(8; 21)(q22; q22.1) AML presents with aberrant CD19 positivity. sciencedirect.com/science/articl…

Cancer in a nutshell

A new paper reviews the associations between acquired aplastic anemia (AA) and germline variants of AA, detailing the clinical significance of germline variants in diagnosing and managing this condition. haematologica.org/article/view/h…

On this Global CML Day, a reminder of the need to ensure that no CML patient is left behind. International CML Foundation Georgia Cancer Center mdpi.com/2072-6694/16/1…

classic morphological 🔬 findings of CML (BCR::ABL1 +) in honor of #WoldCMLDay 09/22 Bone marrow: 1️⃣Left shifted myeloid hyperplasia with eosinophilia 2️⃣Micromegakaryocytes 3️⃣See blue histiocytes #hemepath #leusm #CML

Novel functions for von Willebrand factor ow.ly/rvCi50Tr8cP #thrombosisandhemostasis #vascularbiology